Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.1 SEK | -4.09% | -8.66% | +48.80% |
Sales 2024 * | 52M 4.95M | Sales 2025 * | 393M 37.41M | Capitalization | 2.36B 224M |
---|---|---|---|---|---|
Net income 2024 * | -236M -22.46M | Net income 2025 * | -173M -16.46M | EV / Sales 2024 * | 37.8 x |
Net cash position 2024 * | 391M 37.24M | Net cash position 2025 * | 210M 20M | EV / Sales 2025 * | 5.46 x |
P/E ratio 2024 * |
-13
x | P/E ratio 2025 * |
-8.97
x | Employees | 26 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.03% |
Latest transcript on Vicore Pharma Holding AB
1 day | -4.09% | ||
1 week | -8.66% | ||
Current month | -4.09% | ||
1 month | +0.48% | ||
3 months | +38.45% | ||
6 months | +38.82% | ||
Current year | +48.80% |
Managers | Title | Age | Since |
---|---|---|---|
Ahmed Mousa
CEO | Chief Executive Officer | 40 | 23-09-08 |
Hans Jeppsson
DFI | Director of Finance/CFO | - | 16-12-31 |
Elin Rosendahl
CTO | Chief Tech/Sci/R&D Officer | - | 20-11-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 17-12-31 | |
Chairman | 66 | 17-12-31 | |
Michael Buschle
BRD | Director/Board Member | 64 | 22-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-14 | 21.1 | -4.09% | 158,853 |
24-06-13 | 22 | +0.92% | 155,156 |
24-06-12 | 21.8 | -1.58% | 317,693 |
24-06-11 | 22.15 | -2.42% | 170,302 |
24-06-10 | 22.7 | -1.73% | 253,542 |
Delayed Quote Nasdaq Stockholm, June 14, 2024 at 12:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+48.80% | 224M | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- VICO Stock